We advised the issuer on the SEC-registered offering

Davis Polk advised Smith+Nephew in connection with its SEC-registered shelf takedown of $350 million aggregate principal amount of 5.150% senior notes due 2027 and $650 million aggregate principal amount of 5.400% senior notes due 2034.

Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. Smith+Nephew exists to restore people’s bodies and their self-belief by using technology to take the limits off living. Smith+Nephew calls this purpose ‘Life Unlimited.’ Smith+Nephew’s 18,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of its product portfolio, and the invention and application of new technologies across its three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Founded in Hull, United Kingdom, in 1856, Smith+Nephew now operates in more than 100 countries and generated annual sales of $5.5 billion in 2023.

The Davis Polk corporate team included partners Reuven B. Young and Connie I. Milonakis, European counsel John Taylor and associates Gianna Ceophas, Annie Dulka and Daniel Lindars. Partner Dominic Foulkes, counsel Alon Gurfinkel and associates Freddie Schwier and Ya Sheng Li provided tax advice. All members of the Davis Polk team are based in the London office.

Copy link to share post